Konakion Mm Paediatric Ampoules

Phytomenadione, the active ingredient in Konakion Mm Paediatric Ampoules, is a vitamin K presented as a ampoule for intramuscular, intravenous and oral use. It is used to prevent and treat vitamin K deficiency bleeding in neonates and to reverse anticoagulation caused by vitamin K antagonists.

GNH USA supplies Konakion Mm Paediatric Ampoules as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Konakion Mm Paediatric Ampoules (phytomenadione) is used in the vitamin K pathway to manage bleeding disorders. - Neonatal prophylaxis: prevents hemorrhagic disease of the newborn. - Vitamin K deficiency bleeding: treats bleeding caused by insufficient vitamin K. - Anticoagulant reversal: reverses effects of vitamin K antagonist therapy.

Adverse reactions to phytomenadione may range from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Nausea: transient gastrointestinal upset. - Headache: mild headache.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Thrombosis: unexpected clot formation. - Hemolysis: rare destruction of red blood cells.

When using Konakion Mm Paediatric Ampoules, several precautions should be observed. - Assess vitamin K status: evaluate for deficiency before administration. - Monitor coagulation: check PT/INR after dosing. - Use with caution in newborns: follow neonatal dosing guidelines. - Avoid in patients with known hypersensitivity: do not administer if allergic. - Concomitant anticoagulants: consider interaction with warfarin therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Phytomenadione may interact with several medications, affecting its efficacy or safety.

Major Interactions (Avoid): - Warfarin: antagonizes anticoagulant effect, may reduce INR. - Broad-spectrum antibiotics: may alter gut flora and affect vitamin K synthesis. - Rifampin: induces metabolism, potentially reducing effectiveness.

Moderate Interactions (Monitor Closely): - Heparin: combined effect on coagulation may require monitoring. - Oral contraceptives: possible alteration of clotting balance. - Lipid‑lowering agents (e.g., statins): may affect vitamin K metabolism.